Yamamura T, et al. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD). ECTRIMS 2018, abstract 323.
ECTRIMS 2015 video update Teunissen: Will MS be prevented?
jun 2017